The company plans to conduct clinical development and research and development in parallel across regenerative medicine pipelines in multiple areas, including peripheral nerves, osteochondral tissue and blood vessels, with the aim of obtaining regulatory approval and commercializing the products. It will also leverage public support and collaborative development frameworks.